AtriCure, Inc.

For the period ended Dec 31, 2025. Filed Feb 19, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 19, 2026

ATRC$56.26-2.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

YEARS ENDED DECEMBER 31, 2025, 2024 and 2023

	2025	2024	2023
Revenue	$534,528	$465,307	$399,245
Cost of revenue	133,749	117,783	98,875
Gross profit	400,779	347,524	300,370
Operating expenses:
Research and development expenses	99,209	96,178	73,915
Selling, general and administrative expenses	311,017	291,359	253,138
Total operating expenses	410,226	387,537	327,053
Loss from operations	(9,447)	(40,013)	(26,683)
Other income (expense):
Interest expense	(5,878)	(6,407)	(6,925)
Interest income	4,479	4,434	3,792
Loss on debt extinguishment	—	(1,362)	—
Other income (expense)	683	(326)	(31)
Loss before income tax expense	(10,163)	(43,674)	(29,847)
Income tax expense	1,285	1,024	591
Net loss	$(11,448)	$(44,698)	$(30,438)
Net loss per share:
Basic and diluted net loss per share	$(0.24)	$(0.95)	$(0.66)
Weighted average shares outstanding - basic and diluted	47,750	46,965	46,309
Comprehensive income (loss):
Unrealized gain on investments	$—	$800	$2,898
Foreign currency translation adjustment	1,601	(842)	205
Other comprehensive income (loss)	1,601	(42)	3,103
Net loss	(11,448)	(44,698)	(30,438)
Comprehensive loss, net of tax	$(9,847)	$(44,740)	$(27,335)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.